{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
glutathione disulfide
to a specific field?
Status:
Possibly Marketed Outside US
Source:
NADA141562
(2023)
Source URL:
First approved in 2023
Source:
NADA141562
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
GOHIBIC by InflaRx GmbH
(2023)
Source URL:
First approved in 2023
Source:
GOHIBIC by InflaRx GmbH
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NADA141546
(2022)
Source URL:
First approved in 2022
Source:
NADA141546
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Sotrovimab by GlaxoSmithKline LLC
(2021)
Source URL:
First approved in 2021
Source:
Sotrovimab by GlaxoSmithKline LLC
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA761158
(2020)
Source URL:
First approved in 2020
Source:
BLA761158
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 347
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2015
Source:
21 CFR 355
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00915733: Phase 4 Interventional Completed Myocardial Infarction
(2009)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04656691: Phase 4 Interventional Terminated Covid19
(2021)
Source URL:
Class:
PROTEIN
